Surfix Diagnostics develops diagnostic tests for the early detection and monitoring of cancer utilizing its photonic diagnostics platform with a photonic biosensor as core technology. This easy-to-use, reliable and sensitive biosensor is able to detect multiple biomarkers at the same time. Attractive features that, along with a potentially low unit cost and the ability to easily scale up production, will revolutionize the world of early cancer detection and treatment monitoring.
Photonic biochips use light instead of electricity to detect the presence of biomarkers. The light travels through a spiral-shaped structure on the chip, comparable to a miniature optical fiber.
Receptor molecules that are coated onto the surface of the photonic biochip can selectively catch and bind specific biomarkers in a sample, based on biorecognition.
The interaction between the receptor molecules and the biomarkers causes a change in the properties of the light that is travelling through the chip. This change is detected and translated into a useful diagnostic result, e.g. information about the presence or the concentration of a certain biomarker in the sample.
Artist impression of Surfix’s photonic chip, showing the spiral-shaped structure (white) embedded in the chip like a miniature optical fiber (real dimensions: approx. 0.5 x 0.3 mm2).
Artist impression of Surfix’s photonic biochip with receptor molecules (green, Y-shaped) on the spiral-shaped structure and biomarker molecules (orange spheres).
Reader + biosensor
Surfix Diagnostics' biosensor consists of a photonic biochip and a microfluidic cartridge, in which the sample is processed and the biological assay takes place in a small sample volume. This is comparable to a miniaturized and automated laboratory procedure.
Both the photonic biochip and the microfluidic cartridge benefit from unique proprietary nanocoatings, which enhance the sensitivity of the sensor and the flow of the sample, and reduce unwanted binding of biomolecules.
When the sample is ready for analysis, it is transported to the photonic biochip. The signal read-out of the photonic biosensor is performed with a desktop reader.
The plug-and-play platform is the heart of Surfix Diagnostics' concept in which you, our client and partner, provide the diagnostic application, i.e. the receptor molecule and/or the biomarker you wish to detect.
Your partner Surfix Diagnostics develops a working test to your requirements.
The plug-and-play platform can be used to detect any biomarker, like proteins (antibodies or antigens), nucleic acids (DNA or RNA), viruses, etc.
Surfix Diagnostics combines the photonic biochip and the microfluidic cartridge with smart technologies for fluidic and optical interfacing in a streamlined process flow.
Surfix Diagnostics offers dedicated solutions for assay development, and for scalable production of any diagnostic test with your bioreceptor on the chip to detect your biomarker of interest!